Distribution of lymph node metastasis is a prognostic index in patients with stage III colon cancer

Surgery

Volumn 139, Issue 4, 2006, Pages 516-522

  Kobayashi, Hirotoshi ^a   Ueno, Hideki ^a   Hashiguchi, Yojiro ^a   Mochizuki, Hidetaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VESSEL; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 33646068340     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2005.09.004     Document Type: Article

References (34)

1. American Cancer Society. Cancer facts & figures 2003 (2003), American Cancer Society, Atlanta
2. Muto T., Kotake K., and Koyama Y. Colorectal cancer statistics in Japan. data from JSCCR registration, 1974-1993. Int J Clin Oncol 6 (2001) 171-176
3. Griffin M.R., Bergstralh E.J., Coffey R.J., et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60 (1987) 2318-2324
4. Steinberg S.M., Barkin J.S., Kaplan R.S., and Stablein D.M. Prognostic indicators of colon tumors. the Gastrointestinal Tumor Study Group experience. Cancer 57 (1986) 1866-1870
5. Newland R.C., Chapuis P.H., Pheils M.T., and MacPherson J.G. The relationship of survival to staging and grading of colorectal carcinoma. a prospective study of 503 cases. Cancer 47 (1981) 1424-1429
6. Greene F.L., Page D.L., Fleming I.D., et al. American Joint Committee on Cancer staging manual. 6th ed. (2002), Springer-Verlag, New York
7. Dukes C. The classification of cancer of the rectum. J Pathol 35 (1932) 323-332
8. Phillips R.K., Hittinger R., Blesovsky L., et al. Large bowel cancer. surgical pathology and its relationship to survival. Br J Surg 71 (1984) 604-610
9. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. 5th ed. (1997), Kanehara, Tokyo
10. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed. a secondary survey of intergroup trial INT-0089. J Clin Oncol 21 (2003) 2912-2919
11. Wong J.H., Severino R., Honnebier M.B., et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 17 (1999) 2896-2900
12. Ueno H., Mochizuki H., Hashiguchi Y., and Hase K. Prognostic determinants of patients with lateral nodal involvement by rectal cancer. Ann Surg 234 (2001) 190-197
13. Greene F.L., Stewart A.K., and Norton H.J. A new TNM staging strategy for node-positive (stage III) colon cancer. an analysis of 50,042 patients. Ann Surg 236 (2002) 416-421
14. O'Connell J.B., Maggard M.A., and Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96 (2004) 1420-1425
15. Deddish M.R. Abdominopelvic lymph node dissection in cancer of the rectum and distal colon. Cancer 4 (1951) 1364-1366
16. Sauer I., and Bacon H.E. Influence of lateral spread of cancer of the rectum on radiability of operation and prognosis. Am J Surg 81 (1951) 111-120
17. Swanson R.S., Compton C.C., Stewart A.K., and Bland K.I. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10 (2003) 65-71
18. Pocard M., Panis Y., Malassagne B., et al. Assessing the effectiveness of mesorectal excision in rectal cancer. prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum 41 (1998) 839-845
19. Tepper J.E., O'Connell M.J., Niedzwiecki D., et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19 (2001) 157-163
20. Caplin S., Cerottini J.P., Bosman F.T., et al. For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 83 (1998) 666-672
21. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
22. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer. results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11 (1993) 1879-1887
23. O'Connell M.J., Mailliard J.A., Kahn M.J., et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15 (1997) 246-250
24. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon. results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 (1999) 3553-3559
25. O'Connell M.J., Laurie J.A., Kahn M., et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16 (1998) 295-300
26. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil. impact on disease-free survival and overall survival. J Clin Oncol 15 (1997) 2432-2441
27. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
28. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
29. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. a multicentre randomised trial. Lancet 355 (2000) 1041-1047
30. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
31. Andre T., Bensmaine M.A., Louvet C., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17 (1999) 3560-3568
32. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
33. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
34. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342